Summit Therapeutics Inc. (SMMT): Shareholders' Equity
$658.86M
As of 2025-12-31
$629.98M
As of 2026-06-30
+73.3%
3-year compound annual growth
+52.7%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $658.86M | +69.5% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $388.75M | +400.4% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $77.69M | -38.7% | 2026-02-23, Balance as of period end |
| 2022-12-31 | $126.65M | +52.1% | 2025-02-24, Balance as of period end |
| 2021-12-31 | $83.28M | +4.8% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $79.45M | +0.7% | 2022-12-21, Balance as of period end |
| 2019-12-31 | $78.86M | n/a | 2021-03-31, Balance as of period end |
| 2019-01-31 | $57.59M | n/a | 2021-03-31, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | 2025-12-31 | $658.86M | +69.5% |
| Aurinia Pharmaceuticals Inc. (AUPH) | 2025-12-31 | $581.33M | +54.0% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $567.61M | +29.5% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $174.13M | -57.9% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $502.64M | +25.1% |
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $604.52M | +4.7% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $683.43M | -9.8% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $212.38M | -34.7% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $364.05M | -13.6% |
Compare SMMT, AUPH, KNSA, KURA side by side · Screen every company in Pharmaceutical Preparations ↗